

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 702 728 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
15.04.1998 Bulletin 1998/16

(51) Int Cl.⁶: **C12Q 1/68**

(21) Application number: **94920180.0**

(86) International application number:
PCT/US94/06658

(22) Date of filing: **08.06.1994**

(87) International publication number:
WO 94/29484 (22.12.1994 Gazette 1994/28)

(54) **MAGNETIC CYCLE REACTION**
MAGNETISCHE ZYKLUSREAKTIONEN
REACTION DE CYCLE MAGNETIQUE

(84) Designated Contracting States:
**AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT
SE**

(30) Priority: **09.06.1993 US 74345**

(43) Date of publication of application:
27.03.1996 Bulletin 1996/13

(73) Proprietor: **GAMERA BIOSCIENCE
CORPORATION**
Medford, MA 02155 (US)

(72) Inventor: **MIAN, Alec**
Cambridge, MA 02139 (US)

(74) Representative: **Pett, Christopher Phineas et al**
Frank B. Dehn & Co.,
European Patent Attorneys,
179 Queen Victoria Street
London EC4V 4EL (GB)

(56) References cited:
WO-A-92/04470 **WO-A-92/05443**
WO-A-92/06216 **WO-A-93/09250**
WO-A-93/15224

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

BEST AVAILABLE COPY

EP 0 702 728 B1

Description**BACKGROUND OF THE INVENTION****1. Field of the Invention**

The invention relates to the amplification of specific nucleic acid sequences. More particularly, the invention relates to reagents and processes for carrying out such specific amplification, and to uses thereof.

2. Summary of the Related Art

The ability to amplify specific DNA sequences has greatly facilitated developments in the fields of molecular biology, medicine and forensics. Early processes for amplifying specific DNA sequences, known as PCR, utilized alternating cycles of thermal denaturation of double-stranded DNA molecules followed by reduced temperature annealing of primers to the single strands and extension of the primers by a polymerase to again yield double strands. Mullis, U.S. Patent No. 4,683,202 (1987) discloses such a process, in which new polymerase must be added between cycles to replace the polymerase that has been inactivated by the elevated temperatures of the thermal denaturation step. Mullis *et al.*, U.S. Patent No. 4,683,195 (1987) teaches the use of such a process to detect the presence or absence of a specific nucleic acid sequence in a sample, or to distinguish between different specific nucleic acid sequences in a sample.

These early processes suffered from the considerable inconvenience of having to add polymerase enzyme between cycles. This inconvenience was overcome by the discovery of a purified thermostable DNA polymerase. Gelfand *et al.*, U.S. Patent No. 4,889,818 (1989) discloses a purified thermostable polymerase enzyme from the thermophilic bacterium *Thermus aquaticus*. Mullis *et al.*, U.S. Patent No. 4,965,188 (1990) discloses a process for amplifying specific DNA sequences using the thermostable polymerase, thereby eliminating the need to add polymerase between reaction cycles. Johnson *et al.*, U.S. Patent No. 5,038,852 (1991) discloses an apparatus for automating the polymerase chain reaction using the thermostable polymerase enzyme.

1. International Patent Application, Publication No. WO92/05443 to the Medical Research Council discloses an apparatus for separating a target reagent attached to a solid phase magnetic support from a mixture of reagents.

2. International Patent Application, Publication No. WO92/04470 to Scientific Generics Ltd. discloses a process for denaturing double-stranded nucleic acid in an electrochemical cell by the application of a voltage to the nucleic acid.

The use of a thermostable polymerase enzyme in a thermal denaturation-based chain reaction has reduced the inconvenience of amplifying specific nucleic acid sequences and has helped the method attain broad commercial acceptance. Unfortunately, the use of the thermostable enzyme, which is made necessary by the thermal denaturation step, has imposed serious limitations upon the amplification process. Foremost among these limitations are the fidelity of the amplification process, the size of the nucleic acid sequence that can be amplified, and the time required to carry out the amplification process. The thermostable polymerase enzyme is more prone to errors in the primer extension reaction than are many known polymerases from mesophilic sources. This can be a considerable problem when the amplification process is used preparatively for cloning. In addition, the thermostable polymerase enzyme has been used successfully to amplify nucleic acid sequences of only about 10 kilobases or less. Finally, the thermostable polymerase enzyme polymerizes deoxyribonucleoside triphosphates at a very slow rate. Coupled with the not inconsiderable time required for the thermal denaturation and annealing steps, this slow polymerization results in an amplification process that is measured in hours.

There is, therefore, a need for processes for amplifying specific nucleic acid sequences that overcome the limitations of the thermal cycle-based processes. Ideally, such a process should decrease the time required for the amplification process as well as the size of the target nucleic acid that can be amplified. Most preferably, such a process should rely upon equipment that is mechanically relatively simple.

SUMMARY OF THE INVENTION

The invention provides a process for amplification of specific nucleic acid sequences that is faster than existing methods, has greater fidelity, and can amplify much larger target nucleic acids. This new process is hereby designated "magnetic cycle reaction", or "MCR". The advantages of MCR arise from its use of electromagnetism to effect the strand separation necessary for amplification. Using electromagnetism for strand separation eliminates the need to carry out the amplification process under conditions that destabilize polymerase enzymes. Consequently, the invention provides the convenience of non-stop cyclic amplification of specific nucleic acid sequences without requiring the use of a thermostable enzyme, and instead, mesophilic polymerase enzymes can be used. These mesophilic polymerases catalyze sequence extension at a rate that is at least one and one half orders of magnitude faster than that of the known thermostable polymerases. Moreover, the mesophilic polymerases have much greater fidelity of replication than

the thermostable polymerases. In addition, the mesophilic polymerases are far more processive than the thermostable enzymes, allowing the amplification of target nucleic acids up to 100 or more kilobases in length. Thus, the invention provides specific nucleic acid amplification that is faster and more accurate than existing non-stop methods, and that is applicable to much larger target nucleic acid sequences.

The invention achieves electromagnetic separation of nucleic acid strands by utilizing primer types having two different kinds of bound particles. The first primer type is called a "solid phase primer" and has the primer physically bound to a solid phase or immobile particle or surface. The second primer type is called a "magnetic primer" and is a primer that is physically bound to a particle that is responsive to an electromagnetic field. In the initial steps of the process according to the invention, the solid phase and magnetic phase primers are incorporated into the target nucleic acid sequences, into strands termed the solid phase strand and the magnetic strand. For single-stranded target sequences, this step requires one round each of polymerase extension from the solid phase and magnetic primers, with a single intervening denaturation step. For double-stranded target nucleic acid sequences, the same initial polymerase primer extension steps are used, but each is preceded by a denaturation step. These steps result in a target nucleic acid that has one end attached to a solid phase (via the 5' end of the solid phase strand) and one end attached to a magnetic particle (via the 5' end of the magnetic strand). Once such a target nucleic acid is obtained, amplification is carried out by multiple cycles of first applying a magnetic field to separate the solid phase and magnetic strands, then allowing additional solid phase and magnetic primers to anneal to the separated strands, then finally carrying out conventional polymerase extension from the annealed primers.

The amplification process according to the invention is useful for a variety of purposes. First, the process can be used for diagnostic purposes to determine the presence or absence of a specific target nucleic acid sequence in a sample. In this use, the process according to the invention provides a faster diagnostic approach than existing amplification processes due to the more rapid separation of the target nucleic acid strands and the more rapid polymerization rate of the mesophilic polymerases. Second, the amplification process according to the invention is useful for quantitatively determining the amount of a specific target nucleic acid in a sample, again in a more rapid fashion than is possible with existing amplification processes. The amplification process according to the invention is also useful for preparative uses, such as generating specific target nucleic acid substrates for cloning, sequence analysis and mutagenesis. In this use, the amplification process according to the invention is preferable to existing methods not only due to its greater rapidity, but also because the greater fidelity of the mesophilic polymerases results in fewer mutations in the preparative substrate. In addition, the amplification process according to the invention can be used for nucleic acid mapping, an application that is not possible using existing amplification methods. This use is made possible by the greater processivity of the nucleic acids up to 100 to 200 kilobases in length, compared with the maximum of about 5-10 kilobases obtainable with the less processive thermostable polymerases. This use of the amplification process according to the invention should supplement or replace existing mapping procedures, such as the yeast artificial chromosome cloning approach.

Certain preferred embodiments of the amplification process according to the invention are described in greater detail in the following sections of this application and in the drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic representation of the basic steps of the magnetic cycle reaction using a double-stranded target nucleic acid. Steps 1 and 2 are denaturation and extension steps. Long solid lines represent the initial target nucleic acid strands. Short solid lines represent primers. Stars and circles at the end of the primers represent attached magnetic particles and solid phase surfaces, respectively. Dashed lines represent primer extension products. Step 5 represents electromagnetic pulse separation of target strands, and is followed by annealing of additional magnetic and solid phase primers and polymerase-mediated extension of the primers.

Figures 2A and 2B show a general schematic representation of how the electromagnetic separation of the magnetic particle-bound and solid phase-bound target strands is achieved. A solenoid, 1, is wrapped around a test tube, 2, in which the amplification process takes place. Application of an electric pulse through the solenoid in one direction creates a magnetic field in the direction of the long arrow, 3, shown in Figure 2A. Attachment of one target strand to the solid phase surface, 4, prevents mobility of that strand in response to the magnetic field. In contrast, the other target strand is separated from the first target strand by the magnetic field due to its attachment to a magnetic particle, 5. Reversal of the electric pulse creates a magnetic field in the opposite direction, as shown in Figure 2B. The reversed magnetic field returns the magnetic particle-bound strands and primers, 6, to the vicinity of the solid-phase bound target strands.

Figure 3 shows the experimental scheme used in the experiments described in Example 6. The Figure shows two representative wells of type A (well A) and B (well B) onto each of which a plurality of 750 nucleotide single-stranded DNA molecules have been covalently attached at the 5' of each DNA molecule. The DNA molecules in wells B are radioactively labeled (indicated by an asterisk), while those of wells A are not. In the second step of the experimental

protocol, a plurality of 500 nucleotide single-stranded DNA molecules complementary to the 3' extent of the covalently-attached 750 nucleotide DNA molecules are annealed to the 750 nucleotide DNA molecules in each of the wells A and B. The 500 nucleotide DNA molecules are biotinylated at their 5' ends, and non-covalently attached to streptavidin-coated magnetic beads. These DNA molecules are then extended using T7 DNA polymerase in step 3 of the protocol in the presence (wells A) or absence (wells B) of radiolabeled nucleotide precursors. In step 4, the two DNA strands are separated at 50°C by the application of an external magnetic field, and the separated, extended, magnetic bead-linked strands isolated for electrophoretic analysis. After this separation, the wells were eluted at 90°C and DNA recovered for electrophoretic analysis.

Figure 4 shows the results of electrophoretic analysis of the DNA fragments produced according to Example 6. The first electrophoretic pattern on the left was produced by electrophoresis of radiolabeled 750 nucleotide template DNA and is shown as a control. The positions of the electrophoretic well origin, and of the 750 and 500 nucleotide DNA fragments, are indicated by arrows. The electrophoretic patterns of the DNA recovered by magnetic strand separation (50°C) and thermal denaturation (90°C) from each of the wells A and B are shown.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

The invention relates to the amplification of specific target nucleic acid sequences. The invention provides new reagents and a new process for carrying out such specific nucleic acid amplification.

In the first aspect, the invention provides an improved method for carrying out amplification of specific target nucleic acid sequences that is faster than existing methods, has greater fidelity, and can amplify much larger target nucleic acids. These improvements over existing amplification processes arise from the use of electromagnetism to effect the strand separation necessary for amplification. Accordingly, this new process is designated "magnetic cycle reaction" or "MCR".

The basic steps involved in the MCR process for amplifying a single-stranded target nucleic acid sequence are as follows. First, a solid phase or magnetic primer is incorporated into a nucleic acid strand that is complementary to the target nucleic acid sequence. This step yields a double stranded target nucleic acid that has one strand bound to either a solid phase or magnetic primer, termed respectively, the solid phase strand or the magnetic strand. Second, the target nucleic acid sequence and its complement are denatured. Third, a magnetic or solid phase primer, whichever was not incorporated into the complementary strand, is incorporated into a nucleic acid strand that is homologous to the target nucleic acid sequence, *i.e.*, complementary to the solid phase or magnetic strand. These steps provide a double-stranded nucleic acid sequence that has one strand bound to a solid phase primer (the solid phase strand) and another strand bound to a magnetic primer (the magnetic strand). Fourth, the two strands are separated from each other by applying a magnetic field, in which the solid phase is immobile and the magnetic strand is mobile. Fifth, the separated strands are allowed to anneal to additional solid phase and magnetic primers. In this step, the solid phase strand is allowed to anneal to a magnetic oligonucleotide primer that is complementary to its 3' end, and the magnetic strand is allowed to anneal to a solid phase primer that is complementary to its 3' end. Sixth, the primers that are annealed to the solid phase strand and magnetic strand are extended by a polymerase to provide additional copies of double-stranded nucleic acids that have one strand bound to a solid phase primer and one strand bound to a magnetic primer. Seventh, steps four through six are repeated as many times as necessary to obtain a desired quantity of nucleic acid copies.

The basic steps involved in the MCR process for amplifying a double-stranded target nucleic sequence are the same as for amplifying a single-stranded target nucleic acid sequence, except for the following modifications in the initial steps. Initially, a prefatory denaturation step is necessary to separate the two target nucleic acid strands from each other. Then, the separated target nucleic acid strands are allowed to anneal to primers, with one strand annealing to a solid phase primer and the other strand annealing to a magnetic primer. Next, the primers are extended by a polymerase. These prefatory steps provide two double-stranded target nucleic acids, one of which has one solid phase strand and the other one magnetic strand. The remainder of the process is carried out as described above in steps two through seven for amplification of a single-stranded target nucleic acid.

For purposes of the invention, the term "incorporating a solid phase or magnetic primer into a nucleic acid strand" means hybridizing such a primer to a nucleic acid strand that is complementary to the strand to be synthesized, then extending the primer with a polymerase enzyme in the presence of deoxyribose or ribose nucleoside triphosphates.

For purposes of the invention, the term "magnetic primer" means an oligonucleotide primer that is covalently attached to a particle that is responsive to a magnetic field. Examples of preferred particles for use in such magnetic primers include ferritin molecules and any other metallic particle that is large enough to have a dipole moment, such as Dynabead™ paramagnetic beads (Dynel, Oslo, Norway). The particle should be of a sufficient size to impart a maximum force that will separate the strand bound to the particle from an immobile complementary strand attached to a solid phase. For any given particle, the velocity can be determined empirically and maximum force calculated by the Stoke's relation:

$$F_M = 6\pi nrv$$

where r is the particle's radius, n is the viscosity of the buffer used for amplification and v is the unbound particle's measured velocity through the buffer. For purposes of the invention, the term "solid phase primer" means an oligonucleotide primer that is attached to a solid or immobile phase. In a preferred embodiment the solid phase is controlled pore glass (CPG) and the primer is covalently attached to the solid phase in the conventional manner used for synthesizing oligonucleotides. In another preferred embodiment, the primer is indirectly attached to the solid phase via a receptor-ligand interaction. In this embodiment, a receptor is covalently attached to a solid phase and its ligand is covalently attached to the primer, or *vice versa*. Thus, the primer becomes bound to the solid phase through the non-covalent receptor-ligand binding. Since binding to the solid phase should be very strong, the receptor-ligand affinity should be very high, such as that of the avidin-biotin system, which has an affinity of about 10^{15} /mole. Primers according to the invention are preferably covalently attached to the magnetic particle, solid phase surface, receptor, or ligand. Such attachment may be by a variety of means, and in a preferred embodiment involves the 5' hydroxyl group of the oligonucleotide. The length of the primers is generally the ordinary length for primers used in well-known polymerase chain reaction, and preferably is from about 8 to about 50 nucleotides. For purposes of the invention, a "magnetic strand" is a nucleic acid strand having an incorporated magnetic primer and a "solid phase strand" is a nucleic acid strand having an incorporated solid phase primer.

In the method according to the invention, the denaturation of double-stranded target nucleic acid prior to incorporation of both solid phase and magnetic primers may be carried out in a variety of ways. In one preferred embodiment, such denaturation can be achieved thermally, for example, by subjecting the sample to a temperature of 94°C for about one to about five minutes, preferably for about 2 minutes. In an alternative embodiment, such denaturation can be achieved by exposure of the sample to base, preferably at a pH of from about 13 to about 14. In the first case, subsequent annealing of the solid phase or magnetic primers to the separated strands is achieved by lowering the temperature to below the T_m , usually from about 45°C to about 65°C for up to 5 minutes in the presence of excess primer. In the second case, annealing is carried out in the presence of excess primer by bringing the sample to neutral pH, preferably from about pH 7 to pH 9. In either case the molar excess of primer over target nucleic acid is preferably about 10^3 -fold for cloned target nucleic acids and about 10^6 -fold for genomic target nucleic acids, and most preferably with a primer concentration of about 100 picomoles per reaction. In either case, an appropriate polymerase enzyme is then added in the presence of deoxyribonucleoside or ribonucleoside triphosphates. Appropriate polymerases include any RNA or DNA polymerase from any eukaryotic or prokaryotic organism or virus. Preferred polymerases include T7 DNA polymerase and the *E. coli* DNA polymerase holoenzyme or Klenow fragment. Preferably, the nucleoside triphosphates are deoxyribonucleoside triphosphates and are present at the concentration of about 100-300 μM for each dNTP. Most preferably the primer extension takes place in a buffer also containing about 5-15mM Mg^{2+} , 1mM dithiothreitol (DTT), 0.5mM each of solid phase and magnetic primers, 0-5mM betaine, and having a pH of about 7-8 due to the presence of about 10-20mM Tris-HCl or HEPES buffer at that pH.

Once a solid phase primer has been incorporated into one strand of the target nucleic acid and a magnetic primer has been incorporated into the opposite strand, all further strand separation steps can be undertaken by application of an electromagnetic field. As shown in Figure 2A, attachment of one strand to a solid or immobile phase and pulling of the other strand by an electromagnetic force results in disruption of the base stacking and hydrogen bonding interactions between the strands, culminating in strand separation. The electromagnetic force applied to the double-stranded target nucleic acid should be sufficiently strong to disrupt the base stacking and hydrogen bonding interactions between the strands, but not so strong as to disrupt covalent bonding interactions within the individual strands.

The force necessary to break the weakest intrastrand bond in a DNA molecule is about 368,000 joules/mole, or about 6×10^{-19} joules/molecule. Since work (W) = force (F) x distance (D), then the minimum force necessary to cause intrastrand scission is $F = W/D$. For DNA, the distance through which the force acts is 3.3×10^{-10} meters/molecule (see Smith *et al.*, 1992, *Science* 258: 1122-1126). Thus, the minimum strand scission force,

$$F_s = \frac{6 \times 10^{-19} \text{ joules/molecule}}{3.3 \times 10^{-10} \text{ m molecule}} = 1 \times 10^{-9} \text{ joule/mole} = 1 \times 10^{-9} \text{ Newton (N)}.$$

In contrast, the force necessary to disrupt a DNA duplex molecule is based upon the principal equation:

$$2f / [1-f]^2 C_o = \exp (-\Delta G^\circ/RT),$$

where

C_o = concentration of single-stranded DNA;
 $f = 0.9$ when $T = T_{90}$ (90% dissociated temp.);
 $f = 0.5$ when $T = T_{50}$ (50% dissociation temp. = T_m);
 and $f = 0.1$ when $T = T_{10}$ (10% dissociation temp.).

The temperature dependence of ΔG follows the integrated form of the Gibbs-Helmholtz equation:

$$\Delta G = -T\Delta S + \Delta H.$$

Thus, for a 200-mer,

$$\begin{aligned}\Delta G^\circ &= 31.4 - \Delta G + (\text{initiation energy}) = 26.5 \text{ kcal/mole} \\ \Delta S^\circ &= 0.32928 \text{ kcal/mole} \\ \Delta H^\circ &= 148.8 \text{ kcal/mole and} \\ \Delta G_{90} - \Delta G_{10} &= 31 \text{ kcal/mole, or about } 2 \times 10^{-19} \text{ joules/molecules.}\end{aligned}$$

Thus,

$$F_D = \frac{2 \times 10^{-19} \text{ joules/molecule}}{3.3 \times 10^{-10} \text{ m/molecule}} = 6.1 \times 10^{-10} \text{ N.}$$

According to these value, the dissociation force, F_D , does not approach the scission force, F_S , until the duplex to be dissociated reaches about 600 b.p. At well below this size range, however, duplex dissociation becomes cooperative, allowing complete dissociation without ever reaching F_S .

As indicated, it is beneficial to carry out dissociation at a temperature near the T_m of the duplex. However, the dissociation should occur at a temperature that does not destabilize the polymerase enzyme used for primer extension. Accordingly, it is preferable to use agents that lower the T_m of the duplex. For example, the zwitterion betaine, at $>5M$ concentration, shifts the melting temperature of calf thymus DNA from about $62^\circ C$ to about $48^\circ C$, without affecting protein-DNA interactions at neutral pH. Thus, in a preferred embodiment, MCR is carried out in a buffer containing $>1M$ betaine, most preferably from about $5.2M$ to about $5.6M$ betaine. Alternatively, melting temperature can be reduced by the presence of about $2.4M$ triethyl-ammonium chloride. It should be noted that the use of such agents to reduce melting temperature is generally more desirable when either longer target nucleic acids or target nucleic acids having higher G + C content are involved. Further destabilization of the double helix can be achieved by the addition of single strand binding (ssb) proteins, such as *E. coli* ssb, and/or helicases, such as *E. coli* DNA helicases I, II, and IV (see Wood and Matson, 1987, *J. Biol. Chem.* **262**: 152-169 and 1989, *J. Biol. Chem.* **264**: 82-97). Other chemicals denaturants can also be added in limited quantities to further reduce melting temperature. These denaturants include lower alkyl (1-4 C) alcohols, urea, formamide, and other hydrogen bond competitors. When such chemical denaturants are used, care must be taken to use them in quantities that will not excessively destabilize the polymerase enzyme. Such agents, used properly, can actually have the opposite effect. For example, 10% ethanol actually stabilizes the polymerase enzyme. The combination of various hydrogen bond destabilizing agents in the MCR reaction buffer allows the melting temperature of the target nucleic acid to be reduced such that the MCR can be carried out at a temperature just below the DNA melting temperature, but at which mesophilic polymerases remain stable and active. Carrying out MCR under these conditions ensures that the force required to separate the target nucleic acid strands is well below that level at which intrastrand covalent bond scission occurs.

In a second aspect, the invention provides a rapid quantitative assay for determining the abundance of a specific target nucleic acid in a sample. Such quantitative assays are well known for use with the polymerase chain reaction. (See e.g., Noonan *et al.*, 1990, *Proc. Natl. Acad. Sci. USA* **87**: 7160-7164). The method according to the invention, MCR, can simply be used in place of PCR in the well known quantitative assay that can be carried out in considerably less time than existing assays, due to the speed of MCR, relative to PCR.

In a third aspect, the invention provides an improved process for preparative generation of substrate nucleic acid molecules for cloning, sequence analysis, or mutagenesis. The method according to the invention provides such substrates having fewer mutations than those produced by current amplification procedures, due to the greater fidelity of the mesophilic polymerases. Consequently, the method according to the invention provides more reliable substrates for subsequent molecular biology manipulations.

In a fourth aspect, the invention provides a method for conducting long range genomic mapping. This is made possible by the ability of mesophilic polymerases to amplify target nucleic acids in the 100 to 200 kilobase size range.

Currently, mapping over this size range can be carried out only by the somewhat cumbersome cloning of DNA into yeast artificial chromosomes (YACs). The ability to amplify such large target nucleic acid regions, however, provides a simpler approach. As sequence tag sites (STSs) are identified within the genome at 50-100 kb intervals (*see, e.g. Olson et al., 1989, Science* 245: 1434-1435), the regions between consecutive STSs can conveniently be amplified by the method according to the invention, thereby providing a substrate for more fine-scale mapping by conventional procedures.

The following examples are intended to further illustrate certain preferred embodiments of the invention and are not limiting in nature.

EXAMPLE 1

Determination of the Actual Maximum Force Provided by a Particular Magnetic Particle In An Electromagnetic Field

Dynabead™ paramagnetic beads are obtained from Dynal, Oslo, Norway. The maximum magnetic force acting on the bead is determined by measuring the bead's velocity when traveling through a buffer in a microchamber in response to an electromagnetic field. The microchamber is constructed from a glass slide and sealed coverslip, with the volume between the two occupied by MCR buffer (see Example 4, below). The bead is placed at one end of the sealed, fluid-filled chamber. The slide is then surrounded with a solenoid through which current is passed to create the electromagnetic field. A computer cursor is superimposed on the microscope image and used to record the bead's velocity. Since there is variation between beads, this measurement is taken for several beads. Velocity measurements are made for field strengths that theoretically impose a force upon the bead of 10^{-10} , 5×10^{-9} , 10^{-8} , 5×10^{-8} , 10^{-7} and 5×10^{-7} Newtons. The actual maximum force for the average of several beads is then determined by averaging the observed velocities of the beads and applying the Stokes' relation

$$F_M = 6\pi\eta r v$$

where r is the bead's radius, η the buffer viscosity, and v the bead's velocity. This value is then compared with the theoretical force that the electromagnetic field should have imposed upon the beads, and is thus used to calibrate the electromagnetic field to be used in each of the following examples.

EXAMPLE 2

Determination of the Minimum Force Required to Cause Intrastrand Covalent Bond Scission

Prior to removal of the 5' dimethoxytrityl (DMT) group, a 50-mer oligodeoxynucleotide is biotinylated at its 3' hydroxyl by standard procedures. The DMT group is then removed in aqueous acetic acid and the oligonucleotide purified on C₁₈ HPLC. A glass microscope slide is coated with alkylamidopropanoic acid according to standard procedures. The biotinylated oligonucleotide is then esterified directly to the carboxyl moiety of the alkylamidopropanoic acid. Next, avidin conjugated Dynabead™ paramagnetic beads are added to the objective portion of the slide and unbound beads are rinsed away. The objective portion of the slide is then flooded with MCR buffer (see Example 4) and a coverslip is added. The slide is wrapped in a solenoid, and an electromagnetic field of appropriate strength to generate an actual force of 10^{-10} N on each bead is generated by directing electrical current through the solenoid. The actual force is increased until the oligonucleotides undergo scission at a force of about 10^{-9} N.

$$F = W/D = \frac{6 \times 10^{-19} \text{ J/molecule (for lowest bond dissociation energy in DNA)}}{3.3 \times 10^{-10} \text{ m (maximum extension of single internucleotide linkage)}}$$

Therefore, $F = \sim 2 \times 10^{-9} \text{ joule/molecule} = \sim 2 \times 10^{-9} \text{ N}$.

EXAMPLE 3

Determination of the Minimum Force Necessary for Destabilization of an Oligonucleotide Double Helix

A 3' levulinyl oligonucleotide (50-mer, same as in Example 2) is esterified directly via its 5' hydroxyl to the carboxyl group of alkylamidopropanoic acid coated glass microscope slide. The levulinyl protective group is then removed in

base. A 5'-paramagnetic bead-derivatized 50-mer oligonucleotide having its 10 most 3' nucleotides complementary to the 10 most 3' nucleotides of the glass-bound oligonucleotide is then added in MCR buffer containing T7 DNA polymerase (see Example 4). Extension of the oligonucleotide produces a 90-mer duplex. A coverslip is added and the microscope slide is wrapped in a solenoid and placed on a microscope stage. Electrical current is then directed through the solenoid to generate an actual force upon the paramagnetic beads of about 10^{-10} N. This force is gradually increased until the strands of the duplex are separated at a force of about 6.1×10^{-10} N.

EXAMPLE 4

Amplification Protocol for Amplifying a Target DNA Sequence using MCR

The pBluescript™ SK+1- vector is linearized with *PvuII* and a 210 b.p. fragment spanning the polylinker is amplified as follows. One Manogram digested plasmid is added to an Eppendorf tube containing a solution containing 15mM Tris-HCl (pH 7.5), 10mM MgCl₂, 1mM dithiothreitol (DTT), 0.2mM dNTPs, 0.5mM solid phase primer and 0.5 mM betaine.

The solid phase primer is 5'-AACAGCTATGACCATG-3' (SEQ ID No.:1), with the 5' hydroxyl group esterified to the carboxyl group of alkylamidopropanoic acid-controlled pore glass. The magnetic primer is 5'-GTAAAACGACG-GCCAT-3' (SEQ ID No.:2), with the 5' end biotinylated and linked to a streptavidin-derivatized Dynabead™. The solution is heated to 97°C for 2 minutes, then allowed to cool to 50°C. Ten units of T7 DNA polymerase is then added and the solution is incubated at 45°C for 2 minutes. The solution is heated to 97°C for 2 minutes, then again cooled to 50°C. Ten units of T7 DNA polymerase is added and the solution is again incubated at 45°C for two minutes. The solution is transferred to an MCR machine, with the eppendorf tube fitting within a solenoid at a temperature of 45-50°C. An electromagnetic field of a strength that separates the strands of a duplex, but does not cause scission within a strand (e.g., a field imparting upon each magnetic bead an actual maximum force between about 5×10^{-11} and 1×10^{-9} N) is then applied for 15 seconds; then reversed for 5 seconds, and the solution is incubated at 45-50°C for two minutes. These electromagnetic pulse and incubation steps are then repeated about 20 times. The resulting 210 bp amplified product is then analyzed by gel electrophoresis.

EXAMPLE 5

Amplification of a Target DNA Sequence using MCR

An MCR reaction mixture was assembled containing 30 attomoles of linear lambda phage DNA (~ 100pg) in a solution of 15mM Tris HCl (pH 7.5), 12mM MgCl₂, 50mM NaCl, 1mM dithiothreitol, 0.05mM of each dNTP, 5% glycerol, 5% ethylene glycol, 0.1% TWEEN detergent, and 0.5mM of each of two oligonucleotide primers. One of these primers was the magnetic primer, which is biotinylated at its 5' end and attached non-covalently to streptavidin-coated paramagnetic beads (Dynabead™). The nucleotide sequence of the magnetic primer was:

5'-CGAACAGGTTATCGAATTCAGCCAC-3' (SEQ ID No.:3).

The other primer was the solid phase primer which is covalently attached by the 5' terminal phosphate group to the bottom of a well of a microtitre dish (Covalink, Nunc Inc., Naperville, IL) comprising the reaction vessel in which MCR amplification was performed. The nucleotide sequence of the solid phase primer was:

5'-CATCGTCGTGTATTCCGGACAGTAC-3' (SEQ ID No.:4).

The MCR reaction mixture was heated to 94°C for 1 min, cooled to 50°C and 1-2 Units T7 DNA polymerase was added. Incubation at 50°C was continued for about 1 min. The solution was then heated to 94°C for about 1 min and cooled to 50°C and placed into an MCR apparatus as described above.

1-2 Units of T7 DNA polymerase were added to the MCR reaction mixture and incubated at 45-50° C for the duration of the MCR amplification. An electromagnetic field generated by a solenoid of the MCR apparatus was applied for about 15 sec and then the polarity of the field was reversed for about 5 sec followed by incubation in the absence of the external magnetic field for 5 sec. This cycle of electromagnetic pulses and incubations were repeated an additional 20 times. The resulting 750 bp DNA product was then eluted from the Dynabeads in a solution of 90% formamide/ 10mM EDTA and analyzed by gel electrophoresis. The results of such electrophoretic analysis confirmed amplification of a specific, 750 bp MCR product.

EXAMPLE 6**Demonstration of Strand Separation using Electromagnetic Force**

The ability of a force generated by an applied electromagnetic field having field strength generated by the MCR apparatus described above to separate the strands of a 750 bp double-stranded DNA molecule was determined. Additionally, the assay used for this determination was also used to detect whether any strand scission accompanied DNA duplex denaturation.

The experimental scheme for this assay is shown in Figure 3. Two types of microtitre wells were prepared. In both wells, about 0.2 picomole of a 750 nucleotide, single-stranded DNA fragment was covalently linked to the microtitre well. In wells A, this DNA fragment was unlabeled, while in wells B the DNA fragment was radioactively labeled at its 5' end. Each of the 750 nucleotide fragments in these wells was annealed with a 500 nucleotide, single-stranded DNA molecule complementary to the 3' 500 nucleotides of the 750 nucleotide fragment. The 500 nucleotide fragment was biotinylated at its 5' end and non-covalently linked to streptavidin-coated magnetic beads. T7 DNA polymerase was added in the presence of appropriate buffers, salts and dNTPs and the 500 nucleotide fragment was extended. In wells A, extension was performed in the presence of (³²P)-labeled dCTP, while in wells B no radioactive dNTPs were present. After extension, the extended strands were separated by the application of an external magnetic field as described above at 50°C. The extended product was then eluted from the Dynabeads with a formamide solution as in Example 5 and analyzed by electrophoresis. The wells were then heated to 90°C and the resulting supernatants also analyzed electrophoretically.

The results of these experiments are shown in Figure 4. A sample of the radiolabeled 750 nucleotide template is shown for comparison. In the samples from wells A, radiolabeled (extended) DNA is seen in a broad smear from 500-750 nucleotides, representing the population of DNA molecules extended to varying extents. Further thermal denaturation at 90°C shows essentially no additional radiolabeled DNA, indicating that magnetic separation was quantitative in these experiments. Wells B show no radiolabeled DNA at either 50° or 90°C, indicating that magnetic separation was achieved without significant strand scission, and that covalent attachment of the radiolabeled template strand is stable to heating at 90°C.

These results demonstrate that DNA fragments at least 750 nucleotides in length can be quantitatively separated using an external magnetic field without concomitant strand scission, as predicted from the theoretical discussion presented in Examples 1-3.

SEQUENCE LISTING**(1) GENERAL INFORMATION:****(i) APPLICANT:**

- (A) NAME: Gamera Bioscience
- (B) ADDRESS: 200 Boston Avenue
- (C) CITY: Medford
- (D) STATE: Massachusetts
- (E) COUNTRY: USA
- (F) POSTAL CODE (ZIP): 02155
- (G) TELEPHONE: 617-306-0827
- (H) TELEFAX: 617-306-0837

(ii) TITLE OF INVENTION: Magnetic Cycle Reaction**(iii) NUMBER OF SEQUENCES: 4****(iv) COMPUTER READABLE FORM:**

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)

(v) CURRENT APPLICATION DATA:

APPLICATION NUMBER: PCT/US94/06658

(2) INFORMATION FOR SEQ ID NO:1:

5 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- 10 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

AACAGCTATG ACCATG

16

20 (2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 base pairs
- 25 (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

GTAAAACGAC GGCCAT

14

35 (2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- 40 (A) LENGTH: 25 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

45 (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

CGAACAGGTT ATCGAATTCA GCCAC

25

50 (2) INFORMATION FOR SEQ ID NO:4:

55 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 base pairs

(B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

CATCGTCGTG TATTCCGGAC AGTAC

25

Claims

1. A method of amplifying a specific single-stranded target nucleic acid, the method comprising the steps of:

- (a) incorporating into a nucleic acid strand complementary to the target nucleic acid a solid phase primer to create a solid phase strand bound to the target nucleic acid;
- (b) separating the solid phase strand and the target nucleic acid;
- (c) incorporating into a nucleic acid strand complementary to the solid phase strand a magnetic primer to yield a duplex having one solid phase strand and one magnetic strand;
- (d) separating the solid phase strand from the magnetic strand by applying an electromagnetic field of sufficient strength to dissociate the duplex;
- (e) allowing magnetic primers complementary to the solid phase strand to anneal to the solid phase strand and allowing solid phase primers complementary to the magnetic strand to anneal to the magnetic strand;
- (f) extending the annealed primers with a suitable DNA polymerase; and
- (g) repeating steps (d) through (f) as many times as necessary to obtain a desired quantity of amplified DNA.

2. A method of amplifying a specific single stranded target nucleic acid, the method comprising the steps of:

- (a) incorporating into a nucleic acid strand complementary to the target nucleic acid a magnetic primer to create a magnetic strand bound to the target nucleic acid;
- (b) separating the magnetic strand and the target nucleic acid;
- (c) incorporating into a nucleic acid strand complementary to the magnetic strand a solid phase primer to yield a duplex having one solid phase strand and one magnetic strand;
- (d) separating the solid phase strand from the magnetic strand by applying an electromagnetic field of sufficient strength to dissociate the duplex;
- (e) allowing magnetic primers complementary to the solid phase strand to anneal to the solid phase strand and allowing solid phase primers complementary to the magnetic strand to anneal to the magnetic strand;
- (f) extending the annealed primers with a suitable DNA polymerase; and
- (g) repeating steps (d) through (f) as many times as necessary to obtain a desired quantity of amplified DNA.

3. A method of amplifying a specific double stranded target nucleic acid, the method comprising the steps of:

- (a) separating the strands of the target nucleic acid to yield a first strand and a second strand;
- (b) incorporating a solid phase primer into a strand complementary to the first strand to yield a first heteroduplex having the first strand and a solid phase strand, and incorporating a magnetic primer into a strand complementary to the second strand to yield a second heteroduplex having the second strand and a magnetic strand;
- (c) separating the strands of the first heteroduplex and of the second heteroduplex;
- (d) allowing magnetic primers complementary to the solid phase strand to anneal to the solid phase strand and allowing solid phase primers complementary to the magnetic strand to anneal to the magnetic strand;
- (e) extending the annealed primers with a suitable DNA polymerase;
- (f) separating the solid phase strand from the magnetic strand by applying an electromagnetic field of sufficient strength to dissociate the duplex;
- (g) allowing magnetic primers complementary to the solid phase strand to anneal to the solid phase strand and allowing solid phase primers complementary to the magnetic strand to anneal to the magnetic strand;
- (h) extending the annealed primers with a suitable DNA polymerase; and

(i) repeating steps (f) through (h) as many times as necessary to obtain a desired quantity of amplified DNA.

4. The method according to any one of claims 1 to 3, wherein the magnetic primer is an oligonucleotide bound to a ferritin molecule.

5. The method according to any one of claims 1 to 3, wherein the magnetic primer is an oligonucleotide bound to a paramagnetic bead.

6. The method according to any one of claims 1 to 3, wherein the solid phase primer is an oligonucleotide bound to a glass matrix.

7. The method according to any one of claims 1 to 6, wherein the method takes place in a buffer comprising:

(a) from about 10 to about 20mM Tris-HCl (pH 7-8);

(b) from about 5 to about 15 mM $MgCl_2$;

(c) about 1mM DTT;

(d) from about 0.1 to 0.3 mM each of 4 dNTPs;

(e) about 0.5mM solid phase primer; and/or

(f) about 0.5 mM magnetic primer; and

(g) from about 0 to about 5.6M betaine; and

(h) target nucleic acid.

Patentansprüche

1. Verfahren zur Amplifizierung einer spezifischen einzelsträngigen Ziel-Nucleinsäure, wobei das Verfahren die Schritte umfaßt:

(a) Einbauen eines Festphasenprimers in einen zu der Ziel-Nucleinsäure komplementären Nucleinsäurestrang, wobei ein an die Ziel-Nucleinsäure gebundener Festphasenstrang erzeugt wird,

(b) Trennen des Festphasenstrangs von der Ziel-Nucleinsäure,

(c) Einbauen eines magnetischen Primers in einen zum Festphasenstrang komplementären Nucleinsäurestrang, wobei ein Duplex mit einem Festphasenstrang und einem magnetischen Strang erhalten wird,

(d) Trennen des Festphasenstrangs von dem magnetischen Strang durch Anlegen eines elektromagnetischen Feldes ausreichender Stärke um den Duplex zu dissoziieren,

(e) Annealen lassen von zum Festphasenstrang komplementären magnetischen Primern an den Festphasenstrang und Annealen lassen von zum magnetischen Strang komplementären Festphasenprimern an den magnetischen Strang,

(f) Extendieren der annealten Primer mit einer geeigneten DNA-Polymerase, und

(g) Wiederholen der Schritte (d) bis (f) so oft wie erforderlich um eine gewünschte Menge amplifizierter DNA zu erhalten.

2. Verfahren zur Amplifizierung einer spezifischen einzelsträngigen Ziel-Nucleinsäure, wobei das Verfahren die Schritte umfaßt:

(a) Einbauen eines magnetischen Primers in einen zu der Ziel-Nucleinsäure komplementären Nucleinsäurestrang, wobei ein an die Ziel-Nucleinsäure gebundener magnetischer Strang erzeugt wird,

(b) Trennen des magnetischen Strangs von der Ziel-Nucleinsäure,

(c) Einbauen eines Festphasenprimers in einen zum magnetischen Strang komplementären Nucleinsäurestrang, wobei ein Duplex mit einem Festphasenstrang und einem magnetischen Strang erhalten wird,

(d) Trennen des Festphasenstrangs von dem magnetischen Strang durch Anlegen eines elektromagnetischen Feldes ausreichender Stärke um den Duplex zu dissoziieren,

(e) Annealen lassen von zum Festphasenstrang komplementären magnetischen Primern an den Festphasenstrang und Annealen lassen von zum magnetischen Strang komplementären Festphasenprimern an den magnetischen Strang,

(f) Extendieren der annealten Primer mit einer geeigneten DNA-Polymerase, und

(g) Wiederholen der Schritte (d) bis (f) so oft wie erforderlich um eine gewünschte Menge amplifizierter DNA zu erhalten.

3. Verfahren zur Amplifizierung einer spezifischen doppelsträngigen Ziel-Nucleinsäure, wobei das Verfahren die Schritte umfaßt:

(a) Trennen der Stränge der Ziel-Nucleinsäure, wobei ein erster Strang und ein zweiter Strang erhalten wird,

(b) Einbauen eines Festphasenprimers in einen zum ersten Strang komplementären Strang, wobei ein erster Heteroduplex mit dem ersten Strang und einem Festphasenstrang erhalten wird, und Einbauen eines magnetischen Primers in einen zum zweiten Strang komplementären Strang, wobei ein zweiter Heteroduplex mit dem zweiten Strang und einem magnetischen Strang erhalten wird,

(c) Trennen der Stränge des ersten Heteroduplex und des zweiten Heteroduplex,

(d) Annealen lassen von zum Festphasenstrang komplementären magnetischen Primern an den Festphasenstrang und Annealen lassen von zum magnetischen Strang komplementären Festphasenprimern an den magnetischen Strang,

(e) Extendieren der annealten Primer mit einer geeigneten DNA-Polymerase,

(f) Trennen des Festphasenstrangs von dem magnetischen Strang durch Anlegen eines elektromagnetischen Feldes ausreichender Stärke um den Duplex zu dissoziieren,

(g) Annealen lassen von zum Festphasenstrang komplementären magnetischen Primern an den Festphasenstrang und Annealen lassen von zum magnetischen Strang komplementären Festphasenprimern an den magnetischen Strang,

(h) Extendieren der annealten Primer mit einer geeigneten DNA-Polymerase, und

(i) Wiederholen der Schritte (f) bis (h) so oft wie erforderlich um eine gewünschte Menge amplifizierter DNA zu erhalten.

4. Verfahren nach einem der Ansprüche 1 bis 3, wobei der magnetische Primer ein an ein Ferritin-Molekül gebundenes Oligonucleotid ist.

5. Verfahren nach einem der Ansprüche 1 bis 3, wobei der magnetische Primer ein an ein paramagnetisches Bead gebundenes Oligonucleotid ist.

6. Verfahren nach einem der Ansprüche 1 bis 3, wobei der Festphasenprimer ein an eine Glasmatrix gebundenes Oligonucleotid ist.

7. Verfahren nach einem der Ansprüche 1 bis 6, wobei das Verfahren durchgeführt wird in einem Puffer, umfassend:

(a) von etwa 10 bis etwa 20 mM Tris-HCl (pH 7-8),

(b) von etwa 5 bis etwa 15 mM $MgCl_2$,

(c) etwa 1 mM DTT,

(d) von etwa 0,1 bis 0,3 mM jeweils von 4 dNTPs,

(e) etwa 0,5 mM Festphasenprimer und/oder

5 (f) etwa 0,5 mM magnetischen Primer, und

(g) von etwa 0 bis etwa 5,6 M Betain, und

(h) Ziel-Nucleinsäure.

10

Revendications

15 1. Méthode d'amplification d'un acide nucléique cible monocaténaire spécifique, la méthode comprenant les étapes consistant :

(a) à incorporer dans un brin d'acide nucléique complémentaire de l'acide nucléique cible une amorce de phase solide pour créer un brin de phase solide lié à l'acide nucléique cible ;

(b) à séparer le brin de phase solide et l'acide nucléique cible ;

20 (c) à incorporer dans un brin d'acide nucléique complémentaire du brin de phase solide une amorce magnétique pour obtenir un duplex ayant un brin de phase solide et un brin magnétique ;

(d) à séparer le brin de phase solide du brin magnétique en appliquant un champ électromagnétique de force suffisante pour dissocier le duplex ;

25 (e) à laisser les amorces magnétiques complémentaires du brin de phase solide s'hybrider au brin de phase solide et à laisser les amorces de phase solide complémentaires du brin magnétique s'hybrider au brin magnétique ;

(f) à prolonger les amorces hybridées avec une polymérase d'ADN appropriée ; et

(g) à répéter les étapes (d) à (f) autant de fois que nécessaire pour obtenir une quantité désirée d'ADN amplifiée.

30

2. Méthode d'amplification d'un acide nucléique cible monocaténaire spécifique, la méthode comprenant les étapes consistant :

35 (a) à incorporer dans un brin d'acide nucléique complémentaire de l'acide nucléique cible une amorce magnétique pour créer un brin magnétique lié à l'acide nucléique cible ;

(b) à séparer le brin magnétique et l'acide nucléique cible ;

(c) à incorporer dans un brin d'acide nucléique complémentaire du brin magnétique une amorce de phase solide pour obtenir un duplex ayant un brin de phase solide et un brin magnétique ;

40 (d) à séparer le brin de phase solide du brin magnétique en appliquant un champ électromagnétique de force suffisante pour dissocier le duplex ;

(e) à laisser les amorces magnétiques complémentaires du brin de phase solide s'hybrider au brin de phase solide et à laisser les amorces de phase solide complémentaires du brin magnétique s'hybrider au brin magnétique ;

(f) à prolonger les amorces hybridées avec une polymérase d'ADN appropriée ; et

45 (g) à répéter les étapes (d) à (f) autant de fois que nécessaire pour obtenir une quantité désirée d'ADN amplifiée.

3. Méthode d'amplification d'un acide nucléique cible bicaténaire, la méthode comprenant les étapes consistant :

50 (a) à séparer les brins de l'acide nucléique cible pour obtenir un premier brin et un second brin ;

(b) à incorporer une amorce de phase solide dans un brin complémentaire pour obtenir un premier hétéroduplex ayant le premier brin et un brin de phase solide, et à incorporer une amorce magnétique dans un brin complémentaire du second brin pour obtenir un second hétéroduplex ayant le second brin et un brin magnétique ;

55 (c) à séparer les brins du premier hétéroduplex et du second hétéroduplex ;

(d) à laisser les amorces magnétiques complémentaires du brin de phase solide s'hybrider au brin de phase solide et à laisser les amorces de phase solide complémentaires du brin magnétique s'hybrider au brin magnétique ;

- (e) à prolonger les amorces hybridées avec une polymérase d'ADN appropriée ;
- (f) à séparer le brin de phase solide du brin magnétique en appliquant un champ électromagnétique de force suffisante pour dissocier le duplex ;
- (g) à laisser les amorces magnétiques complémentaires du brin de phase solide s'hybrider au brin de phase solide et à laisser les amorces de phase solide complémentaires du brin magnétique s'hybrider au brin magnétique ;
- (h) à prolonger les amorces hybridées avec les polymérases d'ADN appropriées ; et
- (i) à répéter les étapes (f) à (h) autant de fois que nécessaire pour obtenir une quantité désirée d'ADN amplifiée.

5

10 4. Méthode selon l'une quelconque des revendications 1 à 3, dans laquelle l'amorce magnétique est un oligonucléotide lié à une molécule de ferritine.

15

5. Méthode selon l'une quelconque des revendications 1 à 3, dans laquelle l'amorce magnétique est un oligonucléotide lié à une bille paramagnétique.

6. Méthode selon l'une quelconque des revendications 1 à 3, dans laquelle l'amorce de phase solide est un oligonucléotide lié à une matrice de verre.

20 7. Méthode selon l'une quelconque des revendications 1 à 6, dans laquelle la méthode est mise en oeuvre dans un tampon comprenant :

25

- (a) d'environ 10 à environ 20 mM de Tris HCl (pH 7-8) ;
- (b) d'environ 5 à environ 15 mM de $MgCl_2$;
- (c) environ 1 mM de DTT ;
- (d) d'environ 0,1 à 0,3 mM de chacun des 4 dNTP ;
- (e) environ 0,5 mM d'amorce de phase solide ; et/ou
- (f) environ 0,5 mM d'amorce magnétique ; et
- (g) d'environ 0 à environ 5,6 M de bétaïne ; et
- (h) un acide nucléique cible.

30

35

40

45

50

55

Figure 1




FIG. 2A




FIG. 2B




Figure 3





Figure 4



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.